Drug Trial Radar · NCT04559971
A Phase 1 Study to Evaluate the Safety, Tolerability, PK and PD of SLN124 in Healthy Volunteers
Last checked: Nov 19, 2026Latest source record: Apr 21, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
24
Actual
Start
Sep 3, 2020
Primary completion
Mar 23, 2021
Study completion Mar 23, 2021
Sponsor
- Lead sponsor
- Silence Therapeutics plcIndustry
- Sponsor type
- Industry
- First posted
- Sep 23, 2020
Design
- Study type
- Interventional
- Phase
- Early phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This study will evaluate the safety and tolerability of SLN124 in healthy volunteers.
Conditions
- Healthy Volunteers
Interventions
SLN124Drug
SLN124 for subcutaneous (s.c.) injection
PlaceboDrug
Sodium chloride for s.c. injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse eventsTime frame: 8 weeks
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Hammersmith Medicines Research
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.